FDA Guidance Improves Pregnancy Drug Safety Data
New FDA guidance aims to enhance the collection of pregnancy safety data for drugs and biologics, safeguarding maternal and fetal health during treatment.
The U.S. Food and Drug Administration (FDA) has issued a significant final guidance document, 'Postapproval Pregnancy Safety Studies.' This guidance provides comprehensive recommendations for industry on various methodologies to study the safety of drugs and biological products when used during pregnancy, after they have already been approved for general use.
Historically, pregnant individuals have often been excluded from clinical trials for ethical reasons, leading to a significant knowledge gap regarding medication safety during pregnancy. This new guidance aims to bridge that gap by promoting more robust and ethically sound collection of post-market data.
The recommendations cover a range of methodologies, including observational studies, registries, and the use of real-world data, to gather crucial information on drug exposure and outcomes. The goal is to provide healthcare providers and pregnant patients with more accurate, evidence-based information to make informed treatment decisions.
This guidance is a crucial step towards improving the health and well-being of pregnant individuals and their offspring. By formalizing and improving the standards for post-approval safety studies, the FDA empowers individuals and their clinicians with better information, fostering a more informed and safer healthcare landscape during pregnancy.
The longer view
One headline rarely tells the story. See how today’s news fits the bigger shifts on AI Trends, or learn to read your own data on How it works.